Pharma Exabyte 2015_Draft Agenda

visit our website: www.flemingeurope.com
Pharma Exabyte
2015
Shaping the Next Generation Pharmaceutical R&D with Big Data
</27-28 May 2015>
<Berlin = “Germany”>
<event overview/.>
Big data is a new frontier for pharmaceutical
companies. Its potential in research and development
is enormous and it presents endless opportunities
for every stage of a drug’s development. Pattern
identification, predictive modelling, and more
efficient, diversified-criteria-based clinical trials
are only some of the possibilities big data opens
to pharma companies. However, full integration
of such capabilities requires operational and
organizational transformations that most companies
are still hesitant to implement. Furthermore, there
is a very limited number of case studies available
to learn from.
This event aims to do just that: bring experts who
can offer you knowledge on what, how and when it
can be done.
</what to expect>
18+ speakers and panelists
case studies
keynote speeches
best practices from other industry
practical examples
enhanced networking opportunities
a different format securing more interactivity
intensive discussions boosted by our special
features:
•panel discussions
•The Idea Market
•focused round table discussions
•Fishbowl discussions
</OUR EXPERT SPEAKER & PANELIST FACULTY>
Chris Day, AstraZeneca, UK
Vice President Solution Delivery and Maintenance
Joaquin Dopazo, Centro De Investigacion Principe
Felipe, Spain
Head of the Computational Genomics Department
Manuel Martin Marquez, CERN, Switzerland
Senior Research Fellow & Data Scientist
Mathias Ganz, Ipsen, France
Vice President R&D IT
Hugo Ceulemans, Janssen, Belgium
Associate Scientific Director, Computational
Systems Biology
Athula Herath, MedIummune, UK
Statistical Director
Martin Ryzl, Merck, CZ
GIC Analytics Platform Engineering
Pantaleo Nacci, Novartis Vaccines, Italy
Head Statistical Safety and Epidemiology/PV
TBC
Jerry Lanfear, Pfizer, UK
Head of Research Business Technologies, Europe
Dr Andreas Bender, University of Cambridge, UK
Lecturer for Molecular Informatics and Drug Design
011000010110110101110011011101000110010101110010011001000110000101101101
tel.: +421 257 272 120, fax: +421 255 644 490
[email protected], www.flemingeurope.com
(may 27=[wednesday])
8:30 Registration & Coffee
• What are the opportunities for different R&D stages?
• Is Big Data going to cure the stagnant pipeline and declining
success rates?
• What role will Big Data play in the future?
9:50 Keynote: A special insight from other
industry
• Deployment of big data solutions: advice and limitations
• Reducing operational costs through big data processes
• Success stories
Manuel Martin Marquez, CERN, Switzerland
Senior Research Fellow & Data Scientist
10:20[morning coffee] << & networking;
Addressing the aspects of Big Data: the
3Vs and beyond
Volume
Speed, punchy presentations to start with.
Short presentations delivered by representatives from translational
medicine, clinical research, genomics and drug discovery. Four
different opinions on the Volume will help you to uncover:
• Implication of Big Data in the early phase of drug development
• How to store, handle, reduce and utilize complex data in
translational medicine
• Strategies to eliminate volume-related challenges
• Leveraging large amounts of data to advance patient-centric
treatment
• Next generation of bioinformatics to accelerate the development of
promising treatments
10:50 Statistical Landscaping of therapeutics
effects for the Personal Genomics Era
• Begin with the end in mind, i.e. construct the landscape of health
and treatment outcomes
• Establishing the foundations for mapping personal genomes into
the fold to make precise inferences about the optimal personalised
healthcare interventions
• Utilising the foundation for translation from the bed side to bench
and back of optimal therapeutic interventions and healthcare
decision making processes
Athula Herath, MedIummune, UK
Statistical Director
11:30 An in-depth panel discussion with our
speakers on-spot to dig deeper into:
• Validating biological targets through big data
• Utilization of big data in translational medicine
• Reducing complex data
Velocity
12:00 Speed presentations delivered by
representatives from translational medicine,
clinical research, genomics and drug
discovery. Four different opinions will
cover:
Use of wearables to collect data in real time • Potential of devices such as smartphones or Google Glass
• Processing exponential ,too large, raw and amorphous data
• How to deal with the challenge of velocity for input data?
• Creating dynamic sample size estimations in response to emerging
clinical trial data
DAY
Following the morning presentations, participants will split into groups
and will further discuss the already presented topics. Each table will
have a moderator and three main questions to discuss. After 15
minutes the groups will swap three members with another table and
the discussion will go on with the ideas - brought from the different
group. Each moderator will then present the main outcomes to all
attendees.
Opening Remarks from the Event Chair
9:10 ‚Speed dating session‘: exchange of business
cards among all participants
9:20 {Opening Keynote++}
Are we ready for the era of Big Data?
FORUM
12:40 The Idea Market
9:00 Welcome Note from Fleming Europe
MAIN
13:10{<<luncheon<<}
Variety
Three different speeches, Three different
insight on:
• Use of combined sources to develop drugs for specific patient
populations
• Pooling data from multiple sources to tailor treatments
• Use of combined sources to customize drug development • Discovering new biomarkers through digital pathology
14:10 Large scale and holistic compound scale
activity prediction
• 2D, 3D, physicochemical, high-content imaging and transcriptomics
data at large scale (100k-10M cpds)
• HPC-enabled machine learning
• Joined prediction of activities in 1000s of target-assigned or liabilityassociated assays
Hugo Ceulemans, Janssen, Belgium
Associate Scientific Director, Computational Systems
Biology
14:50 Panel discussion with our speakers to further
investigate:
•
•
•
•
Measuring the impact of big data on R&D
Tools for big data management, analysis and visualization
Implementation of Big Data infrastructure
Linking structured and semi-structured internal data with
unstructured external data to generate Big Data analytics
Veracity, Volatility & Validity
15:20 Spotlight session on uncertainty of data
3 speed presentations followed by a short wrap-up and time for Q&A
• Combining scientific literature with internal and external data
• Unstructured data, uncertain value, expensive exploration
• Creating a semantic data model as a layer
16:00[afternoon tea] << & networking;
16:30 Closing keynote: A look into the future of
medicine
The Virtual Human: In-Silico Methods for
Personalised Medicine
• use of high performance computing to develop personalised drugs
based on a patient’s specific genome
• in silico clinical trials
• modelling and simulation of organ systems for clinical interventions
17:00 The Fishbowl discussion
A 360 degree debate to sum up the main points
discussed
We will have 5 chairs arranged in an inner circle (‘the fishbowl’)
and will start with a ‘closed fishbowl’ with the 5 chairs filled by our
Moderator and Speakers. The audience outside the fishbowl will
first listen in on the discussion and then we will switch to an ‘open
fishbowl’ where one chair will be left empty. Any member of the
audience can, at any time, occupy the empty chair and join the
fishbowl. When this happens, an existing member of the fishbowl
will voluntarily leave the fishbowl. The discussion continues allowing
several people to participate in a focused conversation!
Topics considered for inclusion:
• Impact of next generation sequencing technologies on genomics
• Treating patients, not diseases
• Real World data and studies: How is Real World Data commuting to
translational aspects of R&D
17:45Closing Remarks from the Chairman
Speakers, Delegates and Sponsors are cordially invited to attend the
Cocktail Networking Reception
011000010110110101110011011101000110010101110010011001000110000101101101
tel.: +421 257 272 120, fax: +421 255 644 490
[email protected], www.flemingeurope.com
(may 28=[thursday])
MAIN
FORUM
DAY
8:30 Registration & morning coffee
12:10{<<luncheon<<}
9:00 Opening remarks from the Chairman
13:10 Focused round table discussions
• Changing the mind-set, pursuing a big-data change
program and creating a successful data-centric culture –
gaining value BEFORE identifying an ideal future state
The group will break into smaller groups, each discussing
a different issue. Every group will be led by a round-table
leader, who will lead a lively discussion, ask questions,
spice it up with some controversy and create an open,
uncompetitive atmosphere for idea sharing. At the
conclusion, every chair will summarize the findings of their
discussion and present to the rest of the audience.
• Definition of clear goals
The discussion topics are as follows:
9:10 Opening keynote: Creating Data-Centric
Culture in an organization
• Understanding the real value of big data
1. Oncology
Effective utilization of big data in
various therapeutic areas
9:40Oncology
Case study: From conventional to a perfect
cancer drug
2. Rare diseases
3. Immunology
4. Neurology
13:50 Data Security: Facing the challenge
• Finding the right drug with the help of cloud
computing
• Setting up information management processes to avoid
legal and ethical pitfalls while delivering quality data
• Speeding up the process to identify the right medicine
through predictive analytics platforms
• Ensuring the accuracy and timeliness of data
• data governance issues related to clinical trials(electronic
health records, storage system for clinical data, real
world evidence in trial design)
• What are the struggles with implementation?
10:10[morning coffee] << & networking;
10:40 Rare diseases
Case study: Big data to unlock rare disease’s
secret
14:20 The Fishbowl discussion
A 360 degree debate to sum up the main points
discussed
We will have 5 chairs arranged in an inner circle (‘the
fishbowl’) and will start with a ‘closed fishbowl’ with the 5
chairs filled by our Moderator and Speakers. The audience
outside the fishbowl will first listen in on the discussion
and then we will switch to an ‘open fishbowl’ where one
chair will be left empty. Any member of the audience
can, at any time, occupy the empty chair and join the
fishbowl. When this happens, an existing member of the
fishbowl will voluntarily leave the fishbowl. The discussion
continues allowing several people to participate in a
focused conversation!
• Use large stores of information to identify a genetic
mutation
• From hypothesis to confirmation through data analysis
• Digital health possibilities enabled though viral blogs
and other means
Joaquin Dopazo,
Centro De Investigacion Principe Felipe, Spain
Head of the Computational Genomics Department
11:10Immunology
Case study: Prediction of immunology-related
disease progression
Topics considered for inclusion:
• Predicting disease progression in patients with
established disease from a multi-year registry data set
• How do you open the clinical data to other scientists?
• Cross-functional collaboration to support/allow
successful decision-making
• Utilization of patient-administered survey and annual
in-person patient visit
• Analytics as a tool of Data Visualization
• Securing competitive advantage through strategic
partnerships with patients, the public and industry,
innovative collaboration projects between CROs (or
other vendors) and sponsors 11:40Neurology
Case study: The Brain Initiative
• New dynamic picture of the brain through accelerating
the development and application of innovative
technologies
15:00Closing Remarks from the Chairman
• Big data as a key to treat, cure, and even prevent brain
disorders
• Discovering fundamental insights and addressing brain
diseases through neuron mapping
[farewell] << & networking;